- Page 1:
Clinical Practice Guidelines for th
- Page 4 and 5:
4 Biochemical relapse .............
- Page 6 and 7:
FOREWORD The management of prostate
- Page 8 and 9:
SUMMARY OF CLINICAL PRACTICE RECOMM
- Page 10 and 11:
SUMMARY OF RECOMMENDATIONS Chapter
- Page 12 and 13:
Chapter Recommendations Grade Refs
- Page 14 and 15:
Chapter Recommendations Grade Refs
- Page 16 and 17:
Chapter Recommendations Grade Refs
- Page 18 and 19:
Chapter Recommendations Grade Refs
- Page 20 and 21:
1 INTRODUCTION 1.1 Natural history
- Page 22 and 23:
2 PSYCHOSOCIAL CARE The diagnosis a
- Page 24 and 25:
2.2 Effect of psychological and cog
- Page 26 and 27:
Evidence summary Level References T
- Page 28 and 29:
Recommendation Men with advanced pr
- Page 30 and 31:
An Australian cross-sectional study
- Page 32 and 33:
10. Dunn J, et al. A review of peer
- Page 34 and 35:
41. Sharpley CF, Christie DRH. An a
- Page 36 and 37:
different treatments from different
- Page 38 and 39:
Evidence summary Level References I
- Page 40 and 41:
Evidence summary Level References F
- Page 42 and 43:
Despite these reservations and the
- Page 44 and 45:
For non-metastatic disease there we
- Page 46 and 47:
Evidence summary Level References T
- Page 48 and 49:
monotherapy for low-to-intermediate
- Page 50 and 51:
Evidence summary Level References M
- Page 52 and 53:
for surgery, suggesting that surger
- Page 54 and 55:
Microscopic fully resected node pos
- Page 56 and 57:
All three trials demonstrated impro
- Page 58 and 59:
Evidence summary Level References B
- Page 60 and 61:
of an international multicentre ran
- Page 62 and 63:
45. Melton LJ, III, Alothman KI, Kh
- Page 64 and 65:
76. Little DJ, Kuban DA, Levy LB, Z
- Page 66 and 67:
105. Thompson IM, Tangen CM, Parade
- Page 68 and 69:
4.2 Androgen deprivation therapy (e
- Page 70 and 71:
Evidence summary Level References F
- Page 72 and 73:
therapy since such studies would be
- Page 74 and 75:
apparent in trials comparing CAB wi
- Page 76 and 77: QLQ instrument published by Cleary
- Page 78 and 79: Note: Larger well-powered studies h
- Page 80 and 81: Eight trials examined acute toxicit
- Page 82 and 83: half of patients experienced pain r
- Page 84 and 85: olus) in addition to radiotherapy a
- Page 86 and 87: References 1. Seidenfeld J, Samson
- Page 88 and 89: Cooperative Group. Scandinavian Jou
- Page 90 and 91: Oncology Group, TROG 96.05). Radiot
- Page 92 and 93: trial. European Journal of Cancer 1
- Page 94 and 95: 6 CASTRATION-RESISTANT PROSTATE CAN
- Page 96 and 97: the median overall survival for pat
- Page 98 and 99: There are two points regarding bisp
- Page 100 and 101: with bone pain at study entry. At n
- Page 102 and 103: Recently, there have been reports o
- Page 104 and 105: of these studies 56, 58 and in the
- Page 106 and 107: Side effects (toxicity) As these ra
- Page 108 and 109: hydrocortisone respectively. Tannoc
- Page 110 and 111: 5. Manikandan R, Srirangam SJ, Pear
- Page 112 and 113: 33. Elomaa I, Kylmala T, Tammela T
- Page 114 and 115: 60. Janknegt RA, Abbou CC, Bartolet
- Page 116 and 117: physiotherapists, occupational ther
- Page 118 and 119: 7.5 Q2: Symptom control There was e
- Page 120 and 121: Informal or family caregivers deriv
- Page 122 and 123: 8. Hughes SL, Weaver FM, Giobbie-Hu
- Page 124 and 125: 8 COMPLEMENTARY AND ALTERNATIVE (UN
- Page 128 and 129: 3. Eisenberg DM, Kessler RC, Van Ro
- Page 130 and 131: areas of the state were more likely
- Page 132 and 133: 8 Miller DC, Litwin MS, Bergman J,
- Page 134 and 135: 10 EMERGING THERAPIES It is impossi
- Page 136 and 137: APPENDIX 1 GUIDELINE DEVELOPMENT PR
- Page 138 and 139: study type. Studies published befor
- Page 140 and 141: Grade of recommendation Description
- Page 142 and 143: 2. National Health and Research Cou
- Page 144 and 145: Dr Carole Pinnock AM Principal rese
- Page 146 and 147: Surgery Professor Villis Marshall A
- Page 148 and 149: APPENDIX 3 TNM CLASSIFICATION OF PR
- Page 150 and 151: Summary Prostate T1 T2 T3 T4 N1 M1a
- Page 152 and 153: APPENDIX 4 ABBREVIATIONS AND GLOSSA
- Page 154 and 155: Glossary Actuarial survival A metho
- Page 156 and 157: Effectiveness The extent to which a
- Page 158 and 159: Lymph nodes Small, generally pea-si
- Page 160 and 161: Each stage is divided into subgroup
- Page 162 and 163: APPENDIX 6 - ORGANISATIONS WHICH PR
- Page 164 and 165: Consultant Urologist, Royal Brisban
- Page 166 and 167: No conflict of interest to declare.
- Page 168 and 169: Index to Clinical practice guidelin
- Page 170 and 171: cardiovascular mortality 19, 54, 55
- Page 172 and 173: androgen deprivation therapy (ADT)
- Page 174 and 175: and surgery 32-34 survival 18 toxic
- Page 176 and 177:
and chemotherapy 89-90 see also bon
- Page 178 and 179:
spinal cord compression 62-63 see a
- Page 180 and 181:
systemic 141 Tasmania Association f